What is the recommended management approach for gastroparesis, including dietary measures and pharmacologic therapy?

Gastroparesis Management

Start with dietary modifications (small, frequent, low-fat, low-fiber meals with liquid consistency) for 4 weeks, followed by metoclopramide 10 mg three times daily before meals and at bedtime as first-line pharmacologic therapy if dietary measures fail. 1, 2

Dietary Management

Begin with structured dietary intervention as the foundation of treatment:

• Small, frequent meals (6 meals per day rather than 3 large meals)
• Low-fat content (fat delays gastric emptying)
• Low-fiber content (fiber forms bezoars and delays emptying)
• Small particle size - replace solid foods with liquids, soups, and pureed foods
• Minimum 4-week trial before declaring dietary failure 1

Critical pitfall: Many patients are prematurely labeled as refractory without adequate dietary trials. The small particle size, reduced fat diet must be attempted for at least 4 weeks before escalating therapy 1.

First-Line Pharmacologic Therapy

Metoclopramide (Only FDA-Approved Agent)

Metoclopramide is the only FDA-approved medication for gastroparesis and should be your first-line pharmacologic choice 1, 2.

• Dosing: 10 mg three times daily before meals and at bedtime for minimum 4 weeks 1
• Mechanism: Dual action as prokinetic (dopamine D2 antagonist) and antiemetic
• Black box warning: Tardive dyskinesia risk exists but may be lower than previously estimated 1
• The 2025 AGA guideline issues a conditional recommendation FOR metoclopramide use 2

Alternative Prokinetic: Erythromycin

If metoclopramide fails or is contraindicated:

• Erythromycin accelerates gastric emptying by binding motilin receptors 3, 1
• Conditional recommendation FOR its use 2
• Dosing: Typically 250 mg three times daily (though specific dosing not detailed in guidelines)
• Limitation: Tachyphylaxis develops with chronic use

Medically Refractory Gastroparesis

Definition: Persistent symptoms despite 4 weeks of dietary adjustment AND 4 weeks of metoclopramide 10 mg three times daily (or equivalent first-line therapy) 1

Symptom-Directed Second-Line Therapy

For predominant nausea/vomiting, consider antiemetics:

• 5-HT3 antagonists (ondansetron 4-8 mg 2-3 times daily, granisetron 1 mg twice daily) - up to one-third of patients benefit 1
• Phenothiazines (prochlorperazine 5-10 mg four times daily, chlorpromazine 10-25 mg 3-4 times daily) 1
• Antihistamines (meclizine 12.5-25 mg three times daily) 1

For predominant abdominal pain/discomfort, consider neuromodulators:

• Tricyclic antidepressants: Nortriptyline or desipramine 25-100 mg/day (secondary amines preferred over tertiary amines like amitriptyline due to fewer side effects) 1
• SNRIs: Duloxetine 60-120 mg/day 1
• Anticonvulsants: Gabapentin >1200 mg/day or pregabalin 100-300 mg/day 1

Agents with Conditional Recommendations AGAINST First-Line Use

The 2025 AGA guideline issues conditional recommendations against routine first-line use of 2:

• Domperidone (not FDA-approved in US; available only via investigational protocol)
• Prucalopride (5-HT4 agonist)
• Aprepitant (NK1 antagonist)
• Nortriptyline
• Buspirone
• Cannabidiol

Important context: These agents may still have roles in refractory cases after first-line therapies fail, but should not be initial choices.

Interventional Therapies for Refractory Cases

Reserve these for patients who fail dietary and pharmacologic management:

Endoscopic Interventions

• Gastric per-oral endoscopic myotomy (G-POEM): Conditional recommendation AGAINST routine initial use; reserve for select refractory patients 2
• Botulinum toxin injection into pylorus: Open-label trials show modest temporary improvement, but no placebo-controlled trials exist 3. Use only in highly selected refractory cases 1

Device Therapy

• Gastric electrical stimulation: Conditional recommendation AGAINST routine initial use 2
• Approved under Humanitarian Device Exemption 1
• High-frequency stimulation (12 cpm) improves symptoms with modest gastric emptying changes 3
• Reserve for truly refractory cases after exhausting medical options

Nutritional Support

• Jejunostomy tubes: For enteral nutrition, hydration, and medication administration when oral intake fails 3
• Follow European Society for Clinical Nutrition and Metabolism guidelines for substantial weight loss or intractable vomiting 4

Critical Diagnostic Considerations Before Labeling as Refractory

Before escalating therapy, exclude gastroparesis mimics 1:

Physical examination findings to assess:

• Succussion splash (delayed emptying or gastric outlet obstruction)
• Right upper quadrant bruit (celiac artery compression syndrome)
• Digital ulcers/telangiectasia (scleroderma)
• Ascites/mass/lymphadenopathy (malignancy)

Conditions that mimic refractory gastroparesis:

• Rumination syndrome
• Cyclic vomiting syndrome
• Narcotic bowel syndrome
• Functional dyspepsia
• Intestinal pseudo-obstruction
• Medication-induced (opioids, GLP-1 agonists) - cessation is essential 4

Diagnostic Testing Requirements

Use 4-hour gastric emptying scintigraphy - conditional recommendation AGAINST 2-hour testing 2. Alternative: gastric emptying breath test of mixed composition meal 4.

Management Algorithm Summary

1. Dietary modification (4 weeks minimum): small, frequent, low-fat, low-fiber, liquid-predominant meals
2. First-line pharmacologic: Metoclopramide 10 mg three times daily before meals and at bedtime (4 weeks minimum)
3. Alternative prokinetic: Erythromycin if metoclopramide fails/contraindicated
4. Symptom-directed therapy: Antiemetics for nausea/vomiting; neuromodulators for pain
5. Exclude mimics and medication causes before labeling as refractory
6. Interventional therapies: G-POEM or gastric electrical stimulation only for highly selected refractory patients after medical therapy failure

The most common pitfall is premature escalation to invasive therapies without adequate trials of dietary modification and metoclopramide 1, 2.